IDMA Shocked Over EMR To Novartis

New Delhi: | Updated: Nov 15 2003, 05:30am hrs
The Indian Drug Manufacturers Association on Friday expressed shock over grant of exclusive marketing rights to Novartis India for their drug Glivec. Pointing that some of the domestic manufacturers had already developed their own processes for the drug, association said granting of EMR would give leverage to EMR holder to interfere with generic production and distribution of this drug.

Novartis AG had filed for patent in respect of Glivec in some of the convention countries in May 1993.